TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07053423: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Mucus Plugging and Other Lung Imaging Parameters in Patients With Chronic Obstructive

Sponsor: Sanofi · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 218 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$318,720

Rescue Site Savings

+$212,480

Unlock Full NCT07053423 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07053423 Rescue Dossier →